all benefits of retatrutide Retatrutide: A Multi-Receptor Approach to Weight Management Substack Series 3 of 6:

Retatrutide is not available as a licensed treatment through the NHS, and any use outside of an approved clinical trial would be considered unlicensed

Current Availability and Prescribing Status in the UK Retatrutide is not approved in the UK and is unavailable via the NHS or private prescription

An oral option developed by Eli Lilly is expected to hit the market in early 2Q, and analysts expect demand to be high

In this context, GLP-1R agonists show remarkable potential as an emerging therapeutic agent.GLP-1R agonists reduce body weight, lower blood pressure, and improve lipid levels, as well as exerting anti-inflammatory and antioxidant effects by directly acting on GLP-1R in the heart and blood vessels, thereby reducing the risk of atherosclerotic thrombotic events (Solini et al., 2023)